Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hi turtle, I know you refer to other posters who claimed they added shares, but I do want to reassure you yes there are lot of investors who have kept adding shares, options.
For that reason, for heaven's sake, I can assure you I did buy more shares yesterday, in the last week (call options), ...
The only factor why I have not added much more at this point is restriction of available fund.
My average cost base may be around $ 5 or $6. If I still believe in the game the same way as when I bought those average shares, why would I not buy at $3, $2, and now $1.5?
Trust me, in the last couple of months, most buys are from retail investors, and that trend could change in a sudden, which means the share price could appreciate suddenly as well barring no news.
courtesy of JerryMa, a usual bear who is frequent in IV and Yahooboard; he post this first in Yahoo board, which I checked in Woodford fund site (Jerry must have bought some for quick flip I guess since he has never ever post anything positive about NWBO, now he is quick to post this):
"AMIT THAPER says:
March 10, 2016 5:34 pm
Hi Neil,
Can you provide us with an update on your current thoughts regarding Northwest Biotherapeutics, particularly with regards to the ongoing investigation and how that might impact your investment.
Secondly, can you share your thoughts regarding UCL’s recent T-cell based immunotherapy discovery, and potential impact on Northwest.
Thanks,
Amit
Reply
NEIL WOODFORDMODERATOR says:
Today 2:28 pm
We were pleased that the Northwest board appointed an independent committee to investigate the unsubstantiated claims made in the anonymous so-called research reports. We await the product of that investigation. That aside, we continue to believe in the science behind the DCVax dendritic-cell approach and its long-term potential."
Judged by the response above alone, I think the share price should appreciate significantly if it ought to behaves normally.
Anyhow, I don't care a cent, but this just fortify my buy decision!
Thank you too hopefulsurgonc. You are a few posters I read in this board.
In most time statistic power is one of the most important thing in design. But I think if the company can demonstrate a strong and unequivocal correlation between the significant benefit of DCVax-L in treating the mesenchymal subgroup of patients, it will be no longer a number game.
My only question is can the company provides such a strong and unequivocal correlation? If yes, I don't think FDA will not be persuaded to be a believer.
It then becomes ethics for the FDA to demand anything else. I also believe the failure of CLDX will accelerate this process.
I believe this is what have been behind the scene in negotiation with FDA for its ultimate outright approval under the current trial design by incorporating with new stuff (the request that can make the approval of this subgroup possible under the existing plan).
Various subgroups will be looked at in IAs and final analysis, but it may not be clause or agreement in place in the current plan for the FDA to approval any subgroup, so came my speculation and common sense which I posted yesterday:
"My gut feeling about the current temporary halt and it's a common sense too, though mine:
NWBO initiated the halt while submitting certain trial information seeking for 1) approval for a specific group of patients, the m-subtype patients based on overwhelmingly good and significantly rich data showing DCVax-L can greatly benefit this specific type of patients; or 2) at least add specific clauses into the existing protocol so that when IA analyses or final analysis is conducted this specific group of patients will be specifically analyzed and treated for approval.
While the regulatory process (negotiation, review, etc.) is still going on the trial has gradually reached its specified endpoints: interims. Since the company is not seeking fundamentally change the trial and its goal as some naysayer have argued, the trial will at least be analyzed according to the existing protocol (or part of the protocol if the company is successful to incorporate the aforementioned request into the existing protocol).
Because of this, I believe FDA is still weighing on whether the data is adequate for the request, or whether it should take a look when a prespecified events are reached on the m-subtype of patients and/or the overall patient population.
It is unwise and unethical and dumb for not separating this particular group from the whole in assessing approval as personalized treatment truly gets specific and personal, which is a definite development trend in cancer treatment developments around the world. ..."
Just a final note for today: I keep adding shares and options to my already overweight position.
Notice in the video she intentionally skipped P3 while discussing excitedly about P1 and P3 in order to avoid the world of "controversial" as AF and the like may accuse and it is a wise thing to do so as the regulatory process is still on going
Sorry, I get to do other things, and good luck!
My gut feeling about the current temporary halt and it's a common sense too, though mine:
NWBO initiated the halt while submitting certain trial information seeking for 1) approval for a specific group of patients, the m-subtype patients based on overwhelmingly good and significantly rich data showing DCVax-L can greatly benefit this specific type of patients; or 2) at least add specific clauses into the existing protocol so that when IA analyses or final analysis is conducted this specific group of patients will be specifically analyzed and treated for approval.
While the regulatory process (negotiation, review, etc.) is still going on the trial has gradually reached its specified endpoints: interims. Since the company is not seeking fundamentally change the trial and its goal as some naysayer have argued, the trial will at least be analyzed according to the existing protocol (or part of the protocol if the company is successful to incorporate the aforementioned request into the existing protocol).
Because of this, I believe FDA is still weighing on whether the data is adequate for the request, or whether it should take a look when a prespecified events are reached on the m-subtype of patients and/or the overall patient population.
It is unwise and unethical and dumb for not separating this particular group from the whole in assessing approval as personalized treatment truly gets specific and personal, which is a definite development trend in cancer treatment developments around the world.
Below is a link of LL's 29 Feb 2016 youtube presentation (upload date of course) which I believe is most recent talk she has given and one definitely after the one withdrew some time ago:
"Seeking New Understanding: Novel Approaches to Brain Tumor Therapy"
David Geffen School of Medicine at UCLA, 29 Feb 2016.
Turtle,
It is simple: First I don't believe RS is in the card if no outright bad news is wrapped in LP's sleeves. Any fundamentally bad news should have long been released according to law. And if you still give L a 50/50 shot, the downside is $1.55 and the upside is $10, $20, or whatever you want to put based on your analysis.
I think only D can justify a $5 price if all fuds are subsidised and the current trend for biotech recovery continues.
I am trying to get some extra funds ready in case NW does something unthinkable, unloading his shares which I don't give it a 20% possibility though.
Just ready for the unthinkable. NW IMHO is an idiot, an already proven moron. How could he think LP would give up her controlling stake in the first place? How could he fail his investors by not supporting the share price (or I should say control the share price). It is not that difficult for him to do it. And how could he not buy in the open market at the price below $2?
Sometimes, I hope he just gets out of this space and let me double my shares and go buy tobacco which seems to be his specialty.
This is my last post. Good luck to all longs.
No, not that many.
That's not right. You should be able to bit what the price you are going to accept. BTW, I bought some of it yesterday at $0.25 per call option contract.
"407,000 warrants bought and sold today???"
1) It seems shorts have bought those warrants, at least the majority of the warrants. Because anyone who wants to start a long position, or add to existing position would not buy those expensive warrants as the share price is very low.
Anyone who buys warrants or options is just a pure idiot as he or she can just buy straight shares at such low price of around $2!
So why shorts would buy then? Simply because, if shorts want to buy around 400,000 shares in open market, the share price will fly very high as nobody is willing to sell at this low price range.
So shorts probably shorted sale some shares today, either using borrowed shares or naked to suppressed share price while buying up those "expensive" warrants just in case...
2)
https://clinicaltrials.gov/ updated again on 22 Feb 2016. Nothing changed significantly but the company added one more site: The Valley Hospital in Ridgewood, New Jersey, which is on top of the one German site added on 11 Jan 2016.
So the idiot who is now talking about futility IA in IV can just shut up!
Beartrap, your post is more worthy of all the posts posted in the last few days since the copy&past guru, seemingly neutral, no-nwbo-position taken, huge time DD spender called AVII onboard for sharing his/her free research for anyone who wants to bite, along with other usual bear/short representatives who have long presented.
The reason is simple: their aim is to engage anyone in useless debates with links and seemingly overwhelming copied and pasted authoritative documents and research findings attached, with a string in their hands to control and manipulate.
They are doing their day jobs full time, while your stupid retail investors who have engaged in any "debate" or "discussions" with those "full-time working leads" are willingly heading to a slaughter house, shaked off a few hundred or a thousand shares here and their, or planted doubts, so the shares will be shaked off when price is just appreciated some in the future.
Good job, ladies and gentlemen.
Sometimes, I do think when this board is quiet, the yahoo board is quiet, that would mean NWBO's price must be at $20 or so because all active here these days, either retail sheep and whose with agenda are gone.
Retails have taken loss, slim profits, while the guys working full time will move on to other greener pasture.
"It's amazing how many posts iHub can tell you are new to read but when you block these as your 5, you really don't have much to get through:
RK
Pyrr
iClight
Koman
OutsideLane
What do you know, the names take the form of a pyramid.
Goooooooooooooooooooooooooo NWBO!"
I have additionally added AVII, Austin, the skyisblue or something to the list. I even don't bother to use the ignore button. I just skip all posts from these fellows who work day and night earning their salaries for a not beautiful cause.
Buy, buy, and buy before Woody and other big fish do the same!
I think you have problem of comprehending basic discussion in English. She did say crossover [per se] may not be helping studies with obvious reason in that it will minimize potential benefit in terms of difference of OS between those patients who receive treatment early than those patients who receive treatment later after cross over.
The following is a comment posted to AF's piece today:
"Jo • 22 minutes ago
Adam, did you still remember the day when dndn released its confirmation p3 trial data how the stock market has reacted? Well, dndn released a successful p3 trial confirmation data which met its primary and secondary targets, but yet the stock plunged from double digits to a single digit with a huge volume. So what happened? Today when we looked back it is clear the sudden decline of dndn stock price that day is no doubt due to concerted and coordinated short attacks.
Now back to the case of NWBO. Yes Dr. Liau did have a presentation 15 Oct in which she did say "it seems all patients in the trial are living longer," and it is a good thing for patients but it might not be helping our studies.
Why? Because FDA mandated patients who progressed can receive DCVax vaccine treatment, which is called crossover, so Dr. Liau continued "in reality, we are comparing those who receive DCVax early (in treatment arm) with those who receive later (in placebo arm when patients were crossed over).
Dr. Lieu continued that without crossover "hopefully the difference might be bigger," which means the trial may be still a successful trial with crossover, but it will be much more successful without crossover. And I believe most people listened to Dr. Lieu's presentation have different view with yours.
So it seems Dr. Lieu's remarks are at least quite neutral, but how to explain the sudden 30% price drop on 16 Oct, one day after her presentation?
In my personal opinion and I believe it is also the opinion of most people who have closely observed this company and its stock trend that the answer to that question is as clear as day Mr. Feuerstein: it is due to concerted and coordinated short attacks!"
I have no time to reply.
I agree all you said. OS is too remote to be available for AA.
Personally, I don't believe the current partial halt and behind scene negotiations or reviews with regulatory agencies have anything to do with pseudodepression issue, although it is apparently an issue.
What I wanted to stress is when lengthy discussions are involved in any issues, trial or significant, let alone FUD, some people may tend to look things under microscope while forgetting the overall picture.
Nothing is perfect, the trial design, protocols, enrolment, etc., and if you will, you can always dug out or throw some negative things, but we ought to take thing into perspective.
BTW, investment wise, the stock price of $2 a piece with merely $200 million cap at present is just a joke considering the huge potentials the company can offer.
In most time, the longer the better. When the silence breaks, we will have the smile.
Cheer
Whenever we are discussing on whatever the subject, such as a speculation or some "dug out" fragmental information or data we should always remember what this trial ought to produce in order to be a successful trial:
SS FOUR MONTHS OR MORE PFS, AND SOME OS BENEFIT
All other factors, distractions, havocs and speculations are just that compared to the overall picture, if the trial can meet its preset targets.
So can the trial reach its primary and secondary goals?
According to LL's October presentation, it is most likely the trial had not reach 149 events required for 1st IA yet. So what the company was submitting in Aug/Sep for regulatory review, and what on earth is the reason behind the current ongoing screen halt which began around July?
If Mapman's recent speculation is the case, the company might just want to make sure the havoc caused by pseudoprogression issue on PFS would be able to be corrected as much as possible via negotiation with FDS for some kind of a resolution which can be used to solve the problem more or less if FDA agrees upon, kind of enhancement of the trial if you like, because the trial was still blinded and there was no data available to the company at the time. In Linda' word, it might be called double guarantee, or super conservative.
So why not to do that if the benefits can be maximized, i.e., instead of achieving 4 month PFS, why not to achieve 8 months or more if we can by reasonably requesting to FDA for a resolution? It also deserves to take the pain at this time for long term gain because 4 months is less than 8 months.
The point is that the trial may readily satisfy its preset primary and secondary endpoint requirements if the company had not sought resolution with FDA in the first place (all speculation, not a fact) regardless whether or not there will be an agreed upon resolution or not.
Since October, more than 3 months have passed. If 149 events are reached during this period of time or later, after IA is conducted with good enough efficacy data, AA will still be on the table, why not.
There always are numerous speculations, but we must put our speculations, etc., in perspective. Based on all the information we have known, I have no doubt the trial will meet its primary and secondary targets:
SS FOUR MONTHS OR MORE PFS, AND SOME OS BENEFIT
The current situation is just unbelievable:
It's because all the efforts, much of which I believe are criminal activities, such as naked shorting, secret transactions in dark pools, baseless accusations, etc., aiming to bring down share price to make profits, and the general market perception on biotech on the backdrop of FED first rate hike, the temporary screen halt fiasco, and FED's promised more hike, which led to what we have seen today: unbelievably low share price.
There is a floor for the price. As it becomes so low, even a college kid can gamble on 1k of shares without having impact on his/her studies. If it turns out a good bet, he/she may be able to graduate without any debt and some free money!
Wow, such a beauty of low share price with potential tens or even hundreds of times of returns for the general public which can afford.
A tiny slim of light will trigger a movement and I believe it will happen. woody has to correct himself sooner or latter or just gets out of our way; the silence has to be broken sooner or latter; the nerve of shorts has never been a wire of steel, which will be broken sooner or latter. Most importantly, the long awaiting results will be put in public eye sooner or later...
As long as either of L and D stands fundamentally intact, I am a willing buyer!
Oh, one has openly said he has stake in the company and is a long while the other has always denied he has any stack in the company and is not a short.
So it is easy to see who is more prone to committing criminal activities judged by SEC rules and security laws.
And I do believe there are underground criminal activities going on attacking the company for personal (fund, entity) gains, directly or indirectly.
Smart man,
You better put the two groups together to compare in case you are short sighted.
Now have you ever seen what they are different fundamentally: one group is filled of sensational, slanderous and derogatory attacks on a small biotech company persistently and endlessly at opportunist timing while the other provides his personal analyses on the company based on what we all have known facts at the time.
Since the high profile wall street experts came on board this board with a couple of new posters showing up roughly in the same time with the same color, I have felt more confidence in the chance of a very successful trial of DCVax-L.
Thus my holding is increased to around 300,000, which are big numbers for me for I have never ever put so many eggs in one basket. As the price becomes so low, it becomes much easier to accumulate.
The guy from wall street must loss his contact or hacker during this process so he has to be present in this board to sniff around for new clue.
Sometimes, I hope the share price drops to $1 so I can double my holding in easy.
bye
The fact is that he always does know what he is going to say, this one is no exception, but he chooses only to talk one half of the story or any story as it is usually the case of those who are admittedly not investors, but only "interested in spending endless time doing free DD for those who are interested;" the problem is that Dr. Liau does know better, who helps in a big part design the trial, which "magically" would exclude about 49% of the patient populations who have the best response to DCVax-L. So there is no logic in his so-called DD, a lengthy copy and past type!
The fact is that according to Dr. Liau that "the whole cohort of patients seem to live longer than we would have expected." So if this new FUD is correct, i.e., that big chunk of patients in the most response subtype were "unfortunately" excluded from the trial according to AVII's speculation, then DCVax-L will be not only a success, meaning satisfying its primary goal of 4-months of PFS difference with significant p value, but also a huge, unprecedented success considering that the most popular patient subtype which has the most favorable response has been "by somebody's speculation" excluded from the trial due to "the carelessness, un-professionalism and incompetence" of those who designed the trial.
It is easy to understand all the FUD, if you know who he is.
You may be right. You know all are speculations, but if what you said is right, why the temporary halt have extended to all countries and all sites?
Anyhow, after all the ongoing pains and frustration, it will not satisfy my inner feeling if I lose patience not to wait until approval of at least L or D and until it is unequivocally proven Northwest Biotherapeutics is a huge success story in recent human history.
Or in other word, I will not be happy until share price is fully recognized no matter how long it will take. Of course, the earlier the better.
TC_Trader, I agree and would also like to see a full approval.
But even with a full proval, the haters would still likely spin negativities, such as comparing it to that of DNDN and MNKD so that they can in some degree win some time for either shorts to cover at reasonably not very high price, or new longs to open new positions, etc.
I have prepared for not only seeing its approval, but also at least several quarters of strong commercial data.
A commercial success will finally shut up all haters and see share price in the right place.
Highly likely FDA will handle mesenchymal GBM trial data in the current P3 DCVax-L trial carefully, separately and quickly.
Mesenchymal GBM patients account for almost 50% of all GBM patients.
If the evidence of the extremely long OS of this group of patients is strong and unequivocal, FDA may ask data specifically for this group of patients in the current P3 trial.
It's common sense, even it is not in the initial trial protocol.
So could the certain data from the trial mentioned in the company's news release that the company was submitting for regulatory review are data of this specific group of patients? And could FDA approve the use of DCVax-L specifically for this group of patients before the trial is concluded if the data are proved indeed unequivocally strong?
It is all a speculation until it is a fact.
IT IS BUSINESS AS USUAL LADIES AND GENTLEMEN RE TODAY'S SUPPLEMENTAL FILING:
Woodford needs to have the right/flexibility to sell shares on behalf of his clients. Since he purchased his shares via private placements, the issuer, i.e,, Northwest Biotherapeutics just had to do its courtesy or fulfil its responsibility to register his shares for potential sale;
Also note that Woodford, as clear as the company in today supplement makes, can also sell his shares under Rule 144 if the condition or conditions are met.
This guy has purchased a total of 25,915,937 nwbo shares in which 15,177,739 shares purchased directly from the companies in three times at prices of $5.79, $7.4,and $5.5, and a whopping 10,738,198 shares purchased from open market at prices all the way from around $12 down to probably $7.
He needs to make sure he can sell some in case conditions are right and prices are also right. Or he can sell some shares if his funds face bankruptcy LOL.
I don't think he can sell right away after today's supplement filing, except those shares under Rule 144 of the Securities Act of 1933 that he may be entitled to if he meets the conditions set forth in the rule.
So why it seems suddenly that the two biggest holders (the other is Mr. M, sorry I forgot his full name. Anyway he is the guy holding patents "on behalf" of the company)are being cleared for the right to sell their shares as we enjoy all the time? It is kind of like some companies in the face of potential huge success would usually rash to make stock options ready for all their qualified employees.
Have FDA had a look at efficacy of the L trial? If yes, how any longer can we be kept in dark?
Short interests dropped as I expected as retail fled and some short shares got covered with the cover of those distorted like AF:
12/31/2015 11,545,492 533,918 21.624092
12/15/2015 13,172,981 336,543 39.142044
Sad for those retail investors,and happy I have picked up 30k more during this period.
Sorry, nothing I can come up with at this time, which would be reasonable enough. But if I have to say something, it could be that DMC informed FDA, etc. that the overall cohort of patients have lived and/or not progressed for abnormally longer time than anticipated, or that the number of events has been too much lower than expected, FDA, etc, then asked the company to provide some certain trail information to make sure the trial in general is up to its standard if it decides to have a look at efficacy of the trial.
It could be then back and forth in exchanges of information and opinions between the company, DMC and FDA, etc. while the trial is kept blinded.
The intention of FDA to have a look at efficacy of the trial by itself warranted a partial clinical halt.
For authorities, they may still consider what the next step they will take, and for the company it simply has nothing it can do but wait for the instructions and/or decisions from the authorities.
In the meanwhile, we investors and general public have been kept in dark for almost six months, and the silence will be continual until the company has something worthy of reporting.
Over those six months, other things have to happen which may further compound the overall situation. Maybe the 149 events has reached recently, and so all including FDA are waiting for report.
This is my last post for today. Please see the speculation above as entertainment.
Current partial screening halt has absolutely nothing to do with fast track application, or breakthrough application if it is also mentioned somewhere in company's sec filing.
Many posters have discussed this back and forth for too long a time. It is no common sense for this discussion to continue.
Simply put, it is no reason for such an application to be kept secret for so long a time, if it was not immediately made public on company's own initiatives or on the inquiry of investors.
Fast track at this stage of trial that it is of almost full enrolments, the 149 1st IA may happen anytime or it may have happened, and that the trial could be judged to be a success or failure at anytime, is just a peanut, which IMHO deserves no pursuit; even the company is pursuing it, it makes absolutely no sense to keep it secret.
In instead, we should consider something more profound and more significant!
Hi beartrap,
can you please elaborate a bit more on your following statement, "They have told us that a regulatory board is looking at information verifying that each patient in the trial met all trial requirements"
Is this information you provided in your previous post from annual meeting? How that information was presented?
Thanks.
PS, As far as full enrolment is concerned, I had said that when the trial state was changed from recruiting to active, not recruiting in late October that the news on full enrolment could be likely out in Jan after the number is verified and the last patient is followed with required minimal shots.
I usually don't reply to anyone who is obviously overly biased (in your case, after you made 180° turn recently), let alone those who have never shed a slim of light on things selected, but I would provide this:
It is not rare in blinded, randomized trials in which longer OS of placebo arm or control arm is seen compared to that of design or existing statistics.
In the case of DCVax L trial according to Dr. Liaw, everyone seems to live longer, which may apply to patients in both control and treatment arms, but the so-called placebo effects which have been seen in numerous trials are limited, usually a couple of months or so around the historical or the statistics or the number used in the designs for respective trials.
So if whole cohort of patients experience abnormally longer OS and/or PFS, the placebo effects alone cannot account for it.
That would be a strong indication/suggestion that the underlining trials would be a success.
IMHO, DCVax-L has all the hallmark of that (if the first IA events of 149 patients have not yet been med today,) which is a success, meaning it will satisfy both primary and secondary goals of PFS and OS with ss.
Hi iwasadiver,
I am one of readers in this board who love to read your posts. LL was presenting to kind of "general public" not us investors who are biased in thinking whether the primary goal and/or secondary goal will be med with ss. So it was in this context she was talking OS just as she would be talking to one of her prospective patients in their visits.
So if that being considered, nothing should be confusing at all regarding her video presentation.
I would agree that "every patient seems to live longer" means both mPFS and mOS are longer than expected.
It seems DCVax is working, but how significant is the effect compared to placebo is still yet to be determined.
As the events are kept delayed to be reached, the effect will only go better.
If as of today, the 149 events has indeed not yet happened, I have no doubt the PFS difference will be stellar so will OS.
You are welcome. Also note: "Woodford Investment Management replied that they view the level of due diligence as adequate."
In addition to today's appropriate response from company, I feel it is enough positive information at the time being.
I hail the good move from the company!
This time the company does responds to extremely abnormal share price drop beyond general market turmoil in a way which is appropriate and timely.
I gave Les an email yesterday asking the company to do what usually a responsible company does in cases like that yesterday, and I believe he may have received other inquiries and requests as well.
And glad, I bought lots of yesterday.
Only puzzle that the share price is still this unbelievably low is whether Woody has been limited in participating in open market?
RE Woodford Funds
http://www.whatinvestment.co.uk/financial-news/funds/2501171/now-may-be-a-and39good-time-to-buyand39-the-woodford-patient-capital-trust.thtml
"Towards the end of 2015, one of the holdings in Woodford’s funds suffered a severe share price setback as short sellers criticised the investment. More than one observer commented that such bumps in the road are inevitable because the capital was invested so quickly, and questioned whether Woodford’s firm could have carried out the extensive due diligence required on such nebulous investments. The investment has cost the Woodford funds close to £16 million.
Read more: Neil Woodford breaks silence on US investment that has lost £16 million
Woodford Investment Management replied that they view the level of due diligence as adequate and the investment remains in the portfolio."
TC_Trader,
Thank you for letting us know this information. I think it is a serious information, and will be a great help for the company in pursuing legal actions regarding the long ongoing almost-all-have-known illegal shorting scheme against NWBO. So please forward relevant information to Linda and/or Les.
Thank you for your effort!
Thanks guys. We are on bottom or a few dimes up and down. The next six month chart will be beautiful.
Never ever doubt NW and LP are matured human being, particularly those human being active in business sector.
They are back on the same boat again, although not share the same cabin [according to my yahoo message].
But, I am okay. The longer the temporary-halt related silence the better outcomes!
Need to run for day job. Good luck!
He is not AF. You all have been deceived by someone else. Poor people!
Evidence:
Below is AF's ihub message saying he will tweet:[time:12/17/15 09:13:16 AM] and you will see the time of his tweet at the bottom [time: 6:14 AM - 17 Dec 2015]
So he knew AF's tweet Bluberry first and said he was going to confirm his ID by sending a tweet.
"
Adam_Feuerstein Thursday, 12/17/15 09:13:16 AM
Re: None
Post #
47318
of 47519 Go
Good morning.
My posts last night were met with some doubt about my identity. I assure you, it's really me -- Adam Feuerstein of TheStreet. The guy you love to hate.
To confirm my identity, I will tweet the following from my verified Twitter account:
Blueberry
This will be a "secret" message just for you guys. Check it out at @adamfeuerstein. "
Below is the tweeter message: [time: 6:14 AM - 17 Dec 2015]
" Follow
Adam FeuersteinVerified account
?@adamfeuerstein
Blueberry.
LIKE
1
Fani
6:14 AM - 17 Dec 2015"
Thank you Ready4bluesky,
I knew the initiation of GBM Agile and have totally forgot it after a while. This blog reminds me it has been real.
Something is encouraging: this is an initiation which involves FDA head, leading GBM doctors including Timothy who work side by side with Linda in UCLA, VP Joe Biden, etc., They almost swore to see some light for GMB patients in the near future.
Can DCvax-L is the first dawn light of GMB fighting solution?
Best news for me this week.
Nowadays, conspiracy is everywhere, particularly in Wall Street and even more so in small cap investments.
It no longer needs to be implemented by a bunch of ill-minded persons convened in front of a fireplace with burning wood log spewing FUD;
It no longer needs to be implemented by people communicate with each other wired or wireless planning next strategy and tactics.
Due to the existences of twitter, blogs, high velocity trading with ever sophisticated algorithms probably developed by an Indian or Chinese PhD with broken English and awaiting green card;
Due to our security laws and institutions still the same as they were around the First Great Depression when blacks still did not have the rights to vote, Chinese were banned from entry to the United States out of fear of no fear...And our SEC is known for watching porn in working time, and never ever really put any white collar criminals who are abundant, like Cramer, AF, Martin Shkreli, etc. into jail,
As a drop in a pool of water, the conspiracy in terms of manipulation of nwbo's share price is real and rampant. Evidence has been collected and people behind it better be prosecuted.
But, to counter and win the battle, the best solution will be that whose long investors, particularly Neil Woodford, units to lock as many shares as possible while Linda Powers and her team work diligently, intelligently and efficiently to put the first product of DCVax platform into market.
When data is there, we have no doubt shorts will run on each other in their ways to exit!
I normally don't reply to anyone in my list of INTERNATIONAL category, and you are one in that list, but I may just reply to you for exception today since I am super happy now.
"I think you might mean analogy? I personally don't think it's a bad analogy if NWBO doesn't hurry up and finish the trials or they could be left behind. Also you should do yourself a favor and go back and read all of the posts that stated Linda must have something spectacular up her sleeve that she is holding to gain financing over the years. Never panned out, hence all of the toxic financing until Woodford. It's fact."
You must have messed up with time sequence. We are late in the game in the development of DCVax platform, particularly for L, or someone will point it out we are approaching one of those famous binary events. If LP has nothing of use she would go blindly at the way NW is pointing, but luckily she didn't.
"It's amazing that as soon as someone states something non-pro NWBO, they are shunned and dismissed to move on. Anybody with any view is allowed to post it here, that is what this is for. It's not a cheerleading board. In addition, and I usually wouldn't point this out, if you are going to make fun of someone for an obvious autocorrect error, you should probably go through your email with a fine tooth comb so as to give the proper ANALOGY!"
I have never understood how someone who claims he is long the stock can constantly, persistently and INTERNATIONALLY post ALL negative "messed up" things towards his own long position. You may have your explanation, but I certainly cannot comprehend, hence putting those posters in ignore.
Back to my usual no reply zone and good day.
Beach, you said "The science is sound...but so were AC current, 8-track tapes, betamax tapes, and hybrid cars (circa 1899)"
It is totally different story and you have very poor analogue. At this point of time, LP must have something in terms of trial data, either from 1st or both 1st and 2nd IA. That would be secret weapons to use to have the next finance if she wants to. If data is good, any bankers in WS will line up.
One other fundamental difference is utility. If data is positive enough, L would be used immediately and broadly in the treatment approved.
Ready, I believe you have bailed out as recently as yesterday. It's you decision I have no business to comment. But if any 180° turn makes you happy, pls go on. You really INTERNATIONALLY mess up lots of thing as of late.
As your doubtness on speculation about full enrolment is concerned, all reasoning has been put forward and it still stands. You will see change in filing when the company officially announces it.
As far as Nei Woodford is concerned, he exists to make money for his clients and his reputation. He did what he did, and he will move on. In the case of nwbo, I don't see any gain at this point not to align his interests with LP's and us retail investors.
That means you will gradually see some secret force behind open market buying at starting day of his choosing.
Anyone, the important thing at the time being to think over is whether 1st and/or 2nd IA have happened? What are your assessments/guesses regarding the outcome? Why after 3 long months we are still kept in dark regarding "temporary new screening halt?
You will feel a bit better after you mind exercise. I do.